Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Tyrosine kinase inhibitors Stories

2010-12-06 12:07:46

Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), and how a new gene target functions for several myeloid...

2010-12-06 07:58:00

NEW YORK, Dec. 6, 2010 /PRNewswire/ -- See video from Novartis at: http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=b76c2552-3cd3-4727-8f46-ef825bcb66d4# Novartis announced 24-month data showing that Tasigna® (nilotinib) continues to surpass Glivec® (imatinib)* in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase1. These new data, from the first Phase...

2010-12-06 07:00:00

NEW YORK, Dec. 6, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced today that a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemia who were treated with bosutinib (39 percent) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26 percent) in the intent-to-treat (ITT) population (p=0.002). However, the study did not meet its primary endpoint of superior complete cytogenetic response...

2010-12-06 06:09:00

EAST HANOVER, N.J., Dec. 6, 2010 /PRNewswire/ -- Fewer patients taking Tasigna for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase progressed to advanced stages of the disease 24-month analysis confirms Tasigna induces deeper and more durable cytogenetic and molecular responses Tasigna now approved in the US and Switzerland for this indication; regulatory submissions under review in EU, Japan and other countries worldwide Novartis announced today 24-month...

2010-12-03 16:01:00

NEW YORK, Dec. 3, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced today it is planning regulatory submissions of bosutinib in patients with chronic myeloid leukemia (CML) based on data from a clinical program evaluating the compound in newly diagnosed and previously treated patients. These regulatory submissions are planned for 2011. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) Pfizer has begun the process of preparing a Marketing Authorization Application (MAA)...

2010-12-02 07:00:00

BURLINGTON, Mass., Dec. 2, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the testing rate for epidermal growth factor receptor (EGFR) mutation--a predictor of response to Genentech/Roche/OSI/Chugai's EGFR inhibitor Tarceva--in non-small-cell lung cancer (NSCLC) patients will increase by approximately 50 percent over the next 12 months, according to surveyed U.S. oncologists. In line with...

2010-12-01 13:15:22

Case Western Reserve School of Medicine researchers identify new avenue for gene targeting A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis. While the loss of NOD2, the gene studied in the provoking article, increases the risk of developing Crohn's disease, increased activity of this gene is also thought to exacerbate symptoms. Additionally, activating NOD2...

2010-11-22 06:00:00

SINGAPORE, Nov. 22, 2010 /PRNewswire/ -- S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals. "The advancement of our...

2010-11-20 00:00:47

Results from Phase II biomarker analysis of erlotinib in combination with sorafenib presented at Molecular Targets in Cancer Therapeutic meeting in Berlin, Germany. Broomfield, CO (Vocus) November 19, 2010 Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer (NSCLC) were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in...

2010-11-19 06:55:00

NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when compared to sorafenib, in the study population. Consistent with previous analyses, axitinib demonstrated a generally...